A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for better data on their cost-effectiveness, clinical utility, and their impact on racial and ethnic groups, particularly Black men. The study is published in Annals of Internal Medicine.
Prostate cancer is the most common cancer among men, with cases ranging from barely noticeable to highly aggressive ones requiring serious treatment. Determining who needs which type of treatment remains a significant challenge. Traditionally, clinicians rely on tools like the NCCN guidelines, which assess tumor stage, PSA levels, and Gleason grades. However, these tools are not perfect and can sometimes lead to overtreatment or…